Title
High frequency of the exoU+/exoS+ genotype associated with multidrug-resistant “high-risk clones” of Pseudomonas aeruginosa clinical isolates from Peruvian hospitals
Date Issued
01 December 2019
Access level
open access
Resource Type
journal article
Publisher(s)
Nature Publishing Group
Abstract
The type III secretion system of Pseudomonas aeruginosa is an important virulence factor contributing to the cytotoxicity and the invasion process of this microorganism. The current study aimed to determine the presence of the exoU+/exoS+ genotype in P. aeruginosa clinical isolates. The presence of exoS, exoT, exoU and exoY was determined in 189 P. aeruginosa by PCR, and the presence/absence of exoU was analysed according to source infection, clonal relationships, biofilm formation, motility and antimicrobial susceptibility. The gyrA, parC, oprD, efflux pump regulators and β-lactamases genes were also analysed by PCR/sequencing. The exoS, exoT and exoY genes were found in 100% of the isolates. Meanwhile, exoU was present in 43/189 (22.8%) of the isolates, being significantly associated with multidrug resistance, extensively drug resistance as well as with higher level quinolone resistance. However, the presence of β-lactamases, mutations in gyrA and parC, and relevant modifications in efflux pumps and OprD were not significantly associated with exoU+ isolates. MLST analysis of a subset of 25 isolates showed 8 different STs displaying the exoU+/exoS+ genotype. The MDR basis of the exoU+ isolates remain to be elucidated. Furthermore, the clinical implications and spread of exoU+/exoS+ P. aeruginosa isolates need to be established.
Volume
9
Issue
1
Language
English
OCDE Knowledge area
Virología Políticas de salud, Servicios de salud
Scopus EID
2-s2.0-85069750063
PubMed ID
Source
Scientific Reports
ISSN of the container
20452322
Sponsor(s)
GH has a personal fellowship from the Schlumberger Foundation - Faculty for The Future Program. JR was supported by a fellowship from the I3SNS program (2012–2016), of the ISCIII (grant number: CES11/012). We thank to Angel Sacha for his technical support in the development of microbiological techniques. We thank to Donna Pringle for idiomatic correction. “ISGlobal is a member of the CERCA Programme, Generalitat de Catalunya”.
Sources of information: Directorio de Producción Científica Scopus